NAPROXEN FDA MedWatch Direct Reports Summary

These tables and charts are created from 3,127 voluntary U.S. reports for NAPROXEN (NAPROXEN) reported by individuals to the FDA via the MedWatch Reporting System from 2004 through April 28, 2026.

For a summary of adverse events including mandatory reports submitted by pharmaceutical companies (all countries and all reporter types) to the FAERS database, View FDA FAERS NAPROXEN Report.

NAPROXEN Total Medwatch Safety Reports by Patient Sex

Type of Outcome Reported
Serious: 2276
Not Serious: 851
Note: A serious outcome means the adverse event resulted in death, a life threatening condition, hospitalization, disability, congenital anomaly, or other serious condition.

Suspected Role
Primary Suspect: 3123
Concomitant Drugs: 2525
Note: A single MedWatch report can list more than one drug. This summary includes NAPROXEN identified as the suspect drug or as a concomitantly taken drug.

FDA Safety-Related Labeling Changes

ALEVE (NAPROXEN SODIUM) Over-the-counter Drug:
FDA Safety Communication

FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later because they can result in low amniotic fluid; NSAIDs may cause rare kidney problems in unborn babies

ALEVE (NAPROXEN SODIUM) Over-the-counter Drug:
FDA Safety-related Labeling Changes

NAPRELAN (NAPROXEN SODIUM) Rx Drug:
FDA Safety-related Labeling Changes

ALEVE-D SINUS & COLD (NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE) Over-the-counter Drug:
FDA Safety-related Labeling Changes

TREXIMET (NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE) Rx Drug:
FDA Safety-related Labeling Changes

NAPROSYN (NAPROXEN) Rx Drug:
FDA Safety-related Labeling Changes

ANAPROX (NAPROXEN SODIUM) Rx Drug:
FDA Safety-related Labeling Changes

EC-NAPROSYN (NAPROXEN) Rx Drug:
FDA Safety-related Labeling Changes

For serious adverse events, report them to the FDA by contacting the drug manufacturer or report directly through the MedWatch voluntary reporting form.

NOTES

This report, created by AskaPatient.com, is derived from U.S. drug-related adverse event cases that were reported directly to the FDA using the voluntary MedWatch online or paper reporting system. MedWatch is the voluntary FDA system for consumers, physicians, and others to directly report adverse reactions. The Medwatch initiative was launched in 1993 as a voluntary reporting program for consumers, physicians and other healthcare practitioners.

After processing the received forms, the FDA adds the MedWatch reports to the FDA Adverse Events Reporting System(or FAERS database.) Click here for the complete FAERS report summary, which includes mandatory reports submitted by pharmaceutical companies (worldwide) combined with the MedWatch reports. MedWatch Reports only represent about 5% of the FAERS database. For more, read "Does the FDA's Rapidly Growing Database of Adverse Events Improve Drug Safety?"

The data in this report was obtained from Open FDA. Data was last updated to include reports through January 27, 2026. The reactions, side effects, or "adverse events," represent up to the 20 most frequently occuring events in the database for a drug related to the event. 

Open FDA states that it only includes the most recent version of a case report. It also adds the disclaimer: "Do not rely on Open FDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated."

FDA uses the "MedDRA" classification system to describe reported adverse reactions. MedDRA is a standardized medical terminology that facilitates sharing of regulatory information internationally. In some cases, "patient friendly" terms for the layman designated by MedDRA have been substituted for medical jargon. Please contact us with questions about this report.